CA2773210C - Derivatives of n-hydroxybenzamide for treating hiv infections - Google Patents

Derivatives of n-hydroxybenzamide for treating hiv infections Download PDF

Info

Publication number
CA2773210C
CA2773210C CA2773210A CA2773210A CA2773210C CA 2773210 C CA2773210 C CA 2773210C CA 2773210 A CA2773210 A CA 2773210A CA 2773210 A CA2773210 A CA 2773210A CA 2773210 C CA2773210 C CA 2773210C
Authority
CA
Canada
Prior art keywords
inhibitors
compound according
hiv
day
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2773210A
Other languages
English (en)
French (fr)
Other versions
CA2773210A1 (en
Inventor
Charles Dinarello
Gianluca Fossati
Paolo Mascagni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CA2773210A1 publication Critical patent/CA2773210A1/en
Application granted granted Critical
Publication of CA2773210C publication Critical patent/CA2773210C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2773210A 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections Expired - Fee Related CA2773210C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (it) 2009-10-23 2009-10-23 Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
ITMI2009A001837 2009-10-23
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (2)

Publication Number Publication Date
CA2773210A1 CA2773210A1 (en) 2011-04-28
CA2773210C true CA2773210C (en) 2017-01-03

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773210A Expired - Fee Related CA2773210C (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Country Status (10)

Country Link
US (1) US8637702B2 (enExample)
EP (1) EP2490682A1 (enExample)
JP (1) JP5746196B2 (enExample)
KR (1) KR101687644B1 (enExample)
CN (1) CN102548551A (enExample)
BR (1) BR112012008780A2 (enExample)
CA (1) CA2773210C (enExample)
IN (1) IN2012DN03387A (enExample)
IT (1) IT1396915B1 (enExample)
WO (1) WO2011048514A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345905B2 (en) * 2011-11-29 2016-05-24 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents
MX349767B (es) 2012-02-03 2017-08-11 Italfarmaco Spa Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
AU2005223659A1 (en) * 2004-03-18 2005-09-29 Georgetown University Benzamide and benzoate anti-HIV compounds
ITMI20041347A1 (it) * 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
WO2008097654A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Methods of using saha for treating hiv infection

Also Published As

Publication number Publication date
ITMI20091837A1 (it) 2011-04-23
CN102548551A (zh) 2012-07-04
JP5746196B2 (ja) 2015-07-08
EP2490682A1 (en) 2012-08-29
IN2012DN03387A (enExample) 2015-10-23
IT1396915B1 (it) 2012-12-20
US20120203014A1 (en) 2012-08-09
KR20120083356A (ko) 2012-07-25
BR112012008780A2 (pt) 2020-12-01
KR101687644B1 (ko) 2016-12-19
JP2013508349A (ja) 2013-03-07
CA2773210A1 (en) 2011-04-28
WO2011048514A1 (en) 2011-04-28
US8637702B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
US12083119B2 (en) Methods and compositions for treating viral or virally-induced conditions
CA2773210C (en) Derivatives of n-hydroxybenzamide for treating hiv infections
US8247613B2 (en) Methods and compositions for the synergistic activation of latent HIV
Barbaro et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome
Vandergeeten et al. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir
US20060009527A1 (en) Method of treating TRX mediated diseases
US20190145960A1 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP2175845A2 (en) New combination for use in the treatment of inflammatory disorders
US20230087766A1 (en) Methods of reactivating latent human immunodeficiency virus and related compositions
WO2009007675A2 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
US9956260B1 (en) Treatment of HIV-1 infection and AIDS
Giannakopoulou et al. Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species
AU2009235276A1 (en) New combination for use in the treatment of inflammatory disorders
WO2009007674A2 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
US10633363B2 (en) EPAC1 activators as HIV latency reversal agents (LRA)
US20190292168A1 (en) Novel small molecule brd4 modulators for hiv epigenetic regulation
CA2808492A1 (en) Antifungal agents and uses thereof
Norman Therapeutic approaches to respiratory diseases excluding asthma: Trends from the patent literature 1997-2000
JP2019019109A (ja) 好中球細胞外トラップ形成促進剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150526

MKLA Lapsed

Effective date: 20220914